Prime Capital Investment Advisors LLC Cuts Holdings in Zoetis Inc. $ZTS

Key Points

• Prime Capital Investment Advisors LLC cut its Zoetis stake by 93.2%, selling 49,411 shares in Q4 and leaving it with 3,622 shares valued at $456,000.
• Zoetis beat quarterly expectations with $1.48 EPS on $2.39B revenue, set FY2026 guidance at 7.00–7.10 EPS, and declared a $0.53 quarterly dividend (1.8% yield).
• Analysts are mixed: the consensus rating is "Hold" with a $152.91 price target, while the stock trades near $120 with a market cap of $50.5 billion and a P/E of about 20.

Prime Capital Investment Advisors LLC cut its position in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 93.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 3,622 shares of the company's stock after selling 49,411 shares during the quarter. Prime Capital Investment Advisors LLC's holdings in Zoetis were worth $456,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Banque de Luxembourg S.A. raised its position in Zoetis by 754.0% in the fourth quarter. Banque de Luxembourg S.A. now owns 2,955 shares of the company's stock worth $372,000 after acquiring an additional 2,609 shares during the period. Flagship Harbor Advisors LLC boosted its stake in Zoetis by 14.5% in the fourth quarter. Flagship Harbor Advisors LLC now owns 8,626 shares of the company's stock valued at $1,085,000 after acquiring an additional 1,094 shares during the last quarter. Quilter Plc boosted its stake in Zoetis by 11.0% in the fourth quarter. Quilter Plc now owns 487,241 shares of the company's stock valued at $61,305,000 after acquiring an additional 48,282 shares during the last quarter. Blue Zone Wealth Advisors LLC boosted its stake in Zoetis by 50.0% in the fourth quarter. Blue Zone Wealth Advisors LLC now owns 52,110 shares of the company's stock valued at $6,556,000 after acquiring an additional 17,364 shares during the last quarter. Finally, Secure Asset Management LLC boosted its stake in Zoetis by 12.8% in the fourth quarter. Secure Asset Management LLC now owns 3,087 shares of the company's stock valued at $388,000 after acquiring an additional 351 shares during the last quarter. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research firms have weighed in on ZTS. Morgan Stanley set a $160.00 target price on shares of Zoetis in a research note on Thursday, December 18th. Weiss Ratings cut shares of Zoetis from a "hold (c-)" rating to a "sell (d+)" rating in a research note on Friday, March 27th. Bank of America boosted their target price on shares of Zoetis from $135.00 to $140.00 and gave the company a "neutral" rating in a research note on Friday, February 13th. The Goldman Sachs Group upgraded shares of Zoetis to a "buy" rating in a research note on Monday, December 15th. Finally, Leerink Partners reiterated a "market perform" rating on shares of Zoetis in a research note on Tuesday, March 10th. Six research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus price target of $152.91.

Zoetis Price Performance

Shares of NYSE:ZTS opened at $120.08 on Tuesday. The company has a 50 day moving average of $122.12 and a 200 day moving average of $126.90. The stock has a market cap of $50.51 billion, a P/E ratio of 19.95, a P/E/G ratio of 1.80 and a beta of 0.98. Zoetis Inc. has a 12 month low of $113.29 and a 12 month high of $172.23. The company has a current ratio of 3.03, a quick ratio of 1.94 and a debt-to-equity ratio of 2.71.

Zoetis (NYSE:ZTS - Get Free Report) last issued its quarterly earnings data on Thursday, February 12th. The company reported $1.48 EPS for the quarter, beating the consensus estimate of $1.40 by $0.08. The company had revenue of $2.39 billion during the quarter, compared to analysts' expectations of $2.36 billion. Zoetis had a net margin of 28.24% and a return on equity of 62.02%. Zoetis's revenue for the quarter was up 3.0% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.40 earnings per share. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. As a group, sell-side analysts forecast that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 2nd. Investors of record on Monday, April 20th will be paid a dividend of $0.53 per share. The ex-dividend date of this dividend is Monday, April 20th. This represents a $2.12 annualized dividend and a yield of 1.8%. Zoetis's payout ratio is currently 35.22%.

Zoetis Profile

Zoetis Inc NYSE: ZTS is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company's offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.